| Followers | 680 |
| Posts | 141212 |
| Boards Moderated | 36 |
| Alias Born | 03/10/2004 |
Wednesday, March 03, 2021 10:31:01 AM
Ocugen (OCGN) Jumps After Vaccine Candidate Found 81% Effective
By: TheStreet | March 3, 2021
• Ocugen jumped after an interim analysis of a clinical trial showed its coronavirus-vaccine candidate provided strong protection against COVID-19.
Ocugen (OCGN) shares spiked Wednesday after the eye-drug developer said its partner from India, Bharat Biotech, reported that in an interim analysis of a clinical trial, their coronavirus-vaccine candidate provided strong protection against COVID-19.
The ongoing Phase 3 study of their vaccine candidate, Covaxin, demonstrated a vaccine efficacy of 81%, Ocugen said.
Shares of Ocugen at last check jumped 35% to $13.01.
"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for [emergency use authorization] and approval in the U.S.," Shankar Musunuri, co-founder, chairman and chief executive of Ocugen, said in a statement.
In December, Hyderabad-based vaccine producer Bharat Biotech unveiled a partnership with Ocugen, Malvern, Pa., to develop Covaxin for the U.S. market.
“Today’s results from the interim analysis of Bharat Biotech’s Phase 3 trial of Covaxin mark a milestone in the development of another critical vaccine option for the U.S. market," Bruce Forrest, a physician who sits on the vaccine scientific advisory board of Ocugen, said.
Covaxin is one of the two Covid-19 vaccines approved for emergency use in India, even though efficacy data from its late-stage trial was awaited.
Bharat Biotech Chairman Krishna Ella said Covaxin has also shown “significant immunogenicity” against emerging variants, Bloomberg reported.
The Phase 3 trial that enrolled 25,800 participants aged 18 to 98 “was a challenging task for us,” Ella said.
The interim analysis was based on 43 cases, of which 36 cases of COVID-19 were observed in the placebo group against seven cases seen in a set injected with Covaxin.
Read Full Story »»»
DiscoverGold
By: TheStreet | March 3, 2021
• Ocugen jumped after an interim analysis of a clinical trial showed its coronavirus-vaccine candidate provided strong protection against COVID-19.
Ocugen (OCGN) shares spiked Wednesday after the eye-drug developer said its partner from India, Bharat Biotech, reported that in an interim analysis of a clinical trial, their coronavirus-vaccine candidate provided strong protection against COVID-19.
The ongoing Phase 3 study of their vaccine candidate, Covaxin, demonstrated a vaccine efficacy of 81%, Ocugen said.
Shares of Ocugen at last check jumped 35% to $13.01.
"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for [emergency use authorization] and approval in the U.S.," Shankar Musunuri, co-founder, chairman and chief executive of Ocugen, said in a statement.
In December, Hyderabad-based vaccine producer Bharat Biotech unveiled a partnership with Ocugen, Malvern, Pa., to develop Covaxin for the U.S. market.
“Today’s results from the interim analysis of Bharat Biotech’s Phase 3 trial of Covaxin mark a milestone in the development of another critical vaccine option for the U.S. market," Bruce Forrest, a physician who sits on the vaccine scientific advisory board of Ocugen, said.
Covaxin is one of the two Covid-19 vaccines approved for emergency use in India, even though efficacy data from its late-stage trial was awaited.
Bharat Biotech Chairman Krishna Ella said Covaxin has also shown “significant immunogenicity” against emerging variants, Bloomberg reported.
The Phase 3 trial that enrolled 25,800 participants aged 18 to 98 “was a challenging task for us,” Ella said.
The interim analysis was based on 43 cases, of which 36 cases of COVID-19 were observed in the placebo group against seven cases seen in a set injected with Covaxin.
Read Full Story »»»
DiscoverGold
Information posted to this board is not meant to suggest any specific action, but to point out the technical signs that can help our readers make their own specific decisions. Caveat emptor!
• DiscoverGold
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
